

Journal of Visualized Experiments

Myeloid innate signaling pathway regulation by MALT1 paracaspase activity

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58439R3
Full Title:	Myeloid innate signaling pathway regulation by MALT1 paracaspase activity
Keywords:	MALT1, Paracaspase, Dectin, MINCLE, Toll-Like-Receptor, Protease inhibition, Myeloid cells, CBM complex; MALT1, Paracaspase, Dectin, MINCLE, Toll-Like-Receptor, Protease inhibition, Myeloid cells, CBM complex
Corresponding Author:	Frederic Bornancin SWAZILAND
Corresponding Author's Institution:	
Corresponding Author E-Mail:	frederic.bornancin@novartis.com
Order of Authors:	Frederic Bornancin
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Novarti Campus, Forum 1, WSJ-386, CH-4002 Basel



To: The Editor-In-Chief of *the Journal of Visualized Experiments*

Re: Submission of an article entitled:

**“Myeloid Innate Signaling Pathway Regulation by the
CARD/BCL10/MALT1 Complex”**

As responsible of the research project and on behalf of my coauthors, I would like to submit today our manuscript for consideration. There are no competing financial interests in relation to the work described. None of the submitted material is under consideration elsewhere.

MALT1, a key component of antigen receptor signaling cascades in lymphocytes, has attracted a lot of attention since the discovery of its proteolytic activity in 2008. Current understanding indicates that MALT1 activation occurs during assembly of a canonical “CBM complex”, which relays activation downstream of receptor activation. However, how MALT1 regulates innate signaling pathways is not well understood.

The purpose of this article is to study both human and mouse myeloid systems with selective tool compounds to address which innate pathways depend on MALT1. Several cell types were prepared and analyzed, thus providing guidance for those interested in setting up similar pharmacological approaches using primary cells.

We hope this article can be useful to the research community.

Thank you for your attention.

Best regards,

Frederic Bornancin
Corresponding Author

Frédéric Bornancin, PhD
Senior Research Investigator
Novartis Institutes for BioMedical Research, Forum 1, CH-4056 Basle, Switzerland
Phone: +41 79 444 46 37
Email: frederic.bornancin@novartis.com

TITLE:

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

AUTHORS & AFFILIATIONS:

Adeline Unterreiner^{1*}, Ratiba Touil^{1*}, Daniele Anastasi¹, Nicolas Dubois¹, Satoru Niwa¹, Thomas Calzascia¹, Frédéric Bornancin¹

¹Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Basel, Switzerland

*These authors contribute equally to the manuscript.

E-MAIL ADDRESSES:

Adeline Unterreiner (adeline.unterreiner@novartis.com)

Ratiba Touil (ratiba.touil@novartis.com)

Daniele Anastasi (daniele.anastasi@novartis.com)

Nicolas Dubois (nicolas.dubois@novartis.com)

Satoru Niwa (satoru.niwa@novartis.com)

Thomas Calzascia (thomas.calzascia@novartis.com)

Frédéric Bornancin (frederic.bornancin@novartis.com)

CORRESPONDING AUTHOR:

Frederic Bornancin

KEYWORDS:

MALT1, paracaspase, Dectin, MINCLE, Toll-like receptor, protease inhibition, myeloid cells, CBM complex

SHORT ABSTRACT:

MALT1 regulates innate immunity but how this occurs remains ill-defined. We used the selective MALT1 paracaspase inhibitor MLT-827 to unravel the contribution of MALT1 to innate signaling downstream of Toll-like or C-type lectin-like receptors, demonstrating that MALT1 regulates the production of myeloid cytokines, and downstream of C-type lectin-like receptors, selectively.

LONG ABSTRACT:

Besides its function in lymphoid cells, which has been addressed by numerous studies, the paracaspase MALT1 also plays an important role in innate cells downstream of pattern recognition receptors. Best studied are the Dectin-1 and Dectin-2 members of the C-type lectin-like receptor family that induce a SYK- and CARD9-dependent signaling cascade leading to NF- κ B activation, in a MALT1-dependent manner. By contrast, Toll-like receptors (TLR), such as TLR-4, propagate NF- κ B activation but signal via an MYD88/IRAK-dependent cascade. Nonetheless, whether MALT1 might contribute to TLR-4 signaling has remained unclear. Recent evidence with MLT-827, a potent and selective inhibitor of MALT1 paracaspase activity, indicates that TNF- α production downstream of TLR-4 in human myeloid cells is independent of MALT1, as opposed to TNF- α production downstream of Dectin-1, which is MALT1 dependent. Here, we addressed

the selective involvement of MALT1 in pattern recognition sensing further, using a variety of human and mouse cellular preparations, and stimulation of Dectin-1, MINCLE or TLR-4 pathways. We also provided additional insights by exploring cytokines beyond TNF- α , and by comparing MLT-827 to a SYK inhibitor (Cpd11) and to an IKK β inhibitor (AFN700). Collectively, the data provided further evidence for the MALT1-dependency of C-type lectin-like receptor -signaling by contrast to TLR-signaling.

INTRODUCTION:

The paracaspase activity of MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) was revealed in 2008^{1,2}. Since then, a number of studies have reported its critical contribution to antigen receptor responses in lymphocytes. Genetic models in the mouse as well as pharmacology data support a key role in T cells, in T-cell dependent autoimmunity and in B-cell lymphoma settings^{3,4}. In lymphocytes, MALT1 paracaspase activation occurs upon assembly of a CARD11-BCL10-MALT1 complex⁵, which is triggered by antigen-receptor proximal signaling downstream of the T- or B- cell receptor. There is also ample evidence that a similar CARD9-BCL10-MALT1 complex is important for propagating signals downstream of C-type lectin-like receptors (CLLR), *e.g.*, Dectin-1, Dectin-2 and MINCLE in myeloid cells^{6,7}. Dectin-1 has been particularly well studied because this pathway is critical for host defense against fungal infections^{8,9}. Implication of MALT1 in Toll-like receptor (TLR) pathways, however, has remained controversial¹⁰. Recent evidence in human myeloid cells ruled out a direct role for MALT1 paracaspase activity in the regulation of TNF- α production downstream of TLR-4¹¹.

In the present work, we used various experimental settings and stimulatory conditions in human and mouse myeloid cells to probe innate signaling pathways, relying on specific pharmacological tool inhibitors and measurement of cytokine production.

PROTOCOLS:

Experiments were conducted according to the guidelines and standards of the Novartis Human Research Ethics Committee.

1. Preparation of Peripheral Blood Mononuclear Cells (PBMCs) from Human Buffy Coats

Note: We received buffy coats from healthy volunteers one day after collection, in 50 mL bags. They were provided under informed consent and collected through the *Interregionale Blutspende Schweizerisches Rotes Kreuz*. We handled them using the procedure below, at room temperature unless specified otherwise.

1.1. Prepare a sterile and clean pair of scissors and a 1 L beaker with a plastic bag (under a lamina flow).

1.2. Transfer the buffy coat into the beaker and carefully open it with the scissors.

1.3. Using a 25 mL pipette, add 100 mL of phosphate-buffered saline buffer/ethylenediaminetetraacetic acid (PBS/EDTA: PBS 1x pH 7.4 containing no CaCl_2 and no MgCl_2 , supplemented with 2 mM EDTA pH 8.0).

Note: Using the same pipette and after slowly pipetting the solution up and down, dispense 25 mL of the diluted buffy coat into 6 conical centrifuge tubes of 50 mL pre-filled with 15 mL of polysaccharide-based density gradient.

1.4. Centrifuge 20 min at 800 x g with moderate acceleration (set at 4 out of 9) and without brake to allow for separation of cells based on their densities.

Note: After centrifugation, three layers will be visible; a pellet containing red blood cells and granulocytes, an upper layer made of plasma, and in between a white ring containing peripheral blood mononuclear cells (PBMCs).

1.5. Harvest the PBMC ring using a 10 mL pipette and transfer to new 50 mL tubes.

Note: Two to three 50 mL tubes are normally required per buffy coat. At this stage, some plasma likely contaminates the collected PBMCs, which should have no impact on the subsequent enrichment steps.

1.6. Top up to 50 mL every tube using PBS/EDTA and proceed to three successive washes with decreasing centrifugation time and speed (15 min at 520 x g, 10 min at 330 x g, 8 min at 150 x g).

Note: At each step, the supernatant is poured off in a liquid waste container and the cell pellet is resuspended in 50 mL of PBS/EDTA (pellets may be pooled after the first wash).

1.7. After the final wash, resuspend the pellet in 25 mL of an ice-cold lysis buffer (see **Table of Materials**) to lyse the red blood cells by osmotic pressure.

1.8. Incubate until the solution becomes clear (≤ 5 min at room temperature).

1.9. Stop the reaction by adding 25 mL of separation buffer (PBS 1x pH 7.4 containing no CaCl_2 and no MgCl_2 , supplemented with 2% heat-inactivated fetal bovine serum (FBS) and 1 mM EDTA pH 8.0).

1.10. Wash one more time at 150 x g for 8 min.

Note: At this stage PBMCs can be used as a bulk population (see step 3: PBMCs and monocytes treatments and stimulatory conditions) or processed for monocyte enrichment (see step 2: Preparation of monocytes from PBMCs), or frozen down for subsequent use (see step 5: Monocytes and PBMCs freezing/thawing procedures).

2. Preparation of Monocytes from PBMCs

- 2.1. Resuspend the PBMCs obtained at step 1.10 in separation buffer and count them to reach 5×10^7 cells/mL.
- 2.2. Transfer the cell suspension into a 14 mL conical centrifuge tube with cap.
- 2.3. Add 50 μ L of monocyte enrichment antibody cocktail per mL of cell suspension, vortex, and incubate 10 min at 4 °C.
- 2.4. Add 50 μ L of monocyte enrichment beads per mL of cells.
- Note: The beads must be thoroughly vortexed to ensure homogeneity of the suspension.
- 2.5. After adding the beads, shortly vortex the cell suspension and incubate 5 min at 4 °C.
- 2.6. Rinse the upper part of the tube with separation buffer until the tube is filled up to 10 mL.
- 2.7. Slowly mix the solution by pipetting up and down.
- 2.8. Place the tube without cap into a separation magnet.
- 2.9. Incubate for 2.5 min at room temperature.
- 2.10. Pour slowly into a 15 mL conical centrifuge tube.
- 2.11. At this stage, use monocytes directly (see step 3: PBMCs and monocytes treatments and stimulatory conditions) or differentiate them into immature **Monocyte-derived Dendritic Cells** (iMoDCs) (see step 4), or freeze them down for subsequent use (see step 5).

3. PBMCs and Monocytes Treatments and Stimulatory Conditions

- 3.1. Count cells and dilute them in culture medium (Roswell Park Memorial Institute medium (RPMI) 10% FBS + 1 mM Sodium Pyruvate + 100 U/mL Penicillin Streptomycin (Pen/Strep) + 5 μ M β -mercaptoethanol), down to 1.25×10^4 cells/mL.
- 3.2. Distribute 50 μ L of cell suspension per well of a 384-well plate.
- 3.3. Add 25 μ L of 4x concentrated compound solutions and pre-incubate for 1 h at 37 °C, 5% CO₂.
- 3.4. Add lipopolysaccharide (LPS) to a final concentration of 10 ng/mL, or depleted zymosan (DZ) to a final concentration of 100 μ g/mL, or keep in plain medium.
- 3.5. Incubate overnight at 37 °C, 5% CO₂.

3.6. Take 10 μ L of the supernatant to measure secreted TNF- α levels (see step 7: Cytokines and viability measurements).

4. Monocytes Differentiation into iMoDCs and Stimulatory Conditions

4.1. Count monocytes (enriched at step 2) and centrifuge the cell suspension at 520 x g for 5 min.

4.2. Pipette off the supernatant and add culture medium (RPMI+ 10% FBS to obtain a final cell suspension of 0.4×10^6 cells/mL.

4.3. Add 80 ng/mL recombinant human IL-4 + 100 ng/mL GM-CSF.

4.4. Dispense 5 mL of cell suspension per well in a 6-well plate.

4.5. Incubate for 7 days at 37 °C, 5% CO₂.

4.6. At day 7, harvest cells by pipetting gently to avoid their activation.

4.7. Centrifuge at 520 x g for 5 min.

4.8. Vacuum aspirate and resuspend in 50 mL of culture medium without growth factors.

4.9. Centrifuge at 520 x g for 5 min and resuspend at 1×10^6 cells/mL in culture medium.

4.10. Dispense 100 μ L of cell suspension (10^5 cells) per well of a 96-well flat bottom plate.

4.11. Pre-incubate for 1 h at 37 °C after adding 50 μ L of 4x concentrated compound solutions, prepared as described at step 8: Compounds preparation.

4.12. Add 50 μ L of stimuli (4x concentrated), prepared as described at step 9.

4.13. Incubate 24 h at 37 °C.

4.14. Mix each well and transfer cells and supernatant (SN) into a 96-well V-bottom plate.

4.15. Spin down at 475 x g for 5 min.

4.16. Transfer supernatant into a new 96-well flat bottom plate, seal and freeze at -20 °C until further use.

5. Monocytes and PBMCs Freezing/Thawing Procedures

220 5.1. Freezing

221

222 5.1.1. Spin down PBMC or monocyte cell preparations at 520 x g for 5 min.

223

224 5.1.2. Vacuum aspirate the supernatant and resuspend cells in freezing medium at 1×10^7
225 cells/mL.

226

227 5.1.3. Dispense 1 mL of cell suspension into cryotubes, transfer the tubes to a specific cooling
228 device (see Materials table) and place it at -80°C .

229

230 5.2. Thawing

231

232 5.2.1. Thaw the cryotube and quickly transfer its content into a 15 mL conical centrifuge tube
233 containing 9 mL of culture medium.

234

235 5.2.2. Centrifuge at 520 x g for 5 min.

236

237 5.2.3. Vacuum aspirate supernatant and resuspend cell pellet in 5 mL of culture medium. Cells
238 are now ready for further experimental processing.

239

240 **6. Mouse Spleen Cells Preparation and Treatment**

241

242 Note: We conducted animal sacrifices according to the guidelines and standards of the Novartis
243 Animal Welfare Organization. Studies were approved by the Ethics Committee of the regional
244 governmental authority (*Kantones Veterinäramt der Stadt Basel*). We sacrificed animals by
245 isoflurane over-exposure, with all efforts made to minimize suffering.

246

247 6.1. Harvest the spleen and dissociate tissue using a tube equipped with a mechanical tissue
248 grinder device and filled with 5 mL of cold RPMI medium.

249

250 6.2. Use the spleen program of the dissociation machine to grind organs.

251

252 6.3. Filter the cells through a 100 μm nylon cell strainer.

253

254 6.4. Transfer the suspension into 50 mL tubes and centrifuge at 4°C for 10 min at 320 x g.

255

256 6.5. Vacuum aspirate the supernatant, resuspend the cell pellet in 3 mL of ice-cold lysis buffer,
257 and incubate for ≤ 2 min on ice.

258

259 6.6. Stop lysis by adding 7 mL of RPMI medium.

260

261 6.7. Filter again through a 100 μm nylon cell strainer.

262

263 6.8. Spin down cell suspension at 330 x g for 10 min at 4°C .

264
265 6.9. Vacuum aspirate supernatant and resuspend cells at 11×10^6 cells/mL in complete medium
266 (RPMI supplemented with 10% FBS, 100 U/mL Pen/Step and 5 μ M β -Mercaptoethanol).

267
268 6.10. Plate 1×10^6 cells/well (90 μ L) in a 96-well plate (flat bottom).

269
270 6.11. Add 5 μ L of 20x concentrated compound solution previously diluted in RPMI medium as
271 described in step 8.3: Serial dilution for murine spleen cells.

272
273 6.12. Incubate for 30 min at 37 °C, 5% CO₂.

274
275 6.13. Add 5 μ L of 20x concentrated DZ (final concentration 30 μ g/mL) or 20x concentrated LPS
276 + IFN- γ (TLR-4) (final concentration 1 μ M LPS and 10 ng/mL IFN- γ).

277
278 6.14. Incubate overnight at 37 °C, 5% CO₂.

279
280 6.15. Centrifuge at 330 x g for 10 min.

281
282 6.16. Transfer supernatants in new plates, seal and freeze at -20 °C until further use.

283 284 **7. Cytokines and Viability Measurements**

285
286 7.1. Human TNF- α measurement by HTRF (Homogenous Time Resolved Fluorescence)

287
288 Note: The protocol followed the supplier's recommendations, briefly summarized below.

289
290 7.1.1. Mix 1 volume of reconstituted reagent (anti TNF- α -cryptate and anti-TNF- α -XL665) with
291 19 volumes of reconstitution buffer (50 mM phosphate buffer pH 7.0, 0.8 M potassium fluoride
292 (KF), 0.2% bovine serum albumin (BSA)).

293
294 7.1.2. Mix the two ready-to-use antibody solutions 1:1 just prior to dispensing the reagents.

295
296 7.1.3. Dispense 10 μ L of supernatants from step 3.6 into white 384-well plates.

297
298 7.1.4. Dispense 10 μ L of the antibody mix.

299
300 7.1.5. Cover the plate with a sealer and incubate at 4 °C overnight.

301
302 7.1.6. Read plate on a microplate reader (50-200 flash).

303
304 7.2. Human IL-23 measurement by HTRF (Homogenous Time Resolved Fluorescence)

305
306 Note: The protocol followed the supplier's recommendations, briefly summarized below.

7.2.1. Mix one volume of reconstituted reagent (anti IL-23-cryptate-antibody and anti-IL-23 D2-antibody) with 19 volumes of detection buffer #3.

7.2.2. Mix the two ready-to-use antibody solutions 1:1 just prior to dispensing the reagents.

7.2.3. Dispense 10 μ L of supernatants from step 3.6 into white 384-well plates.

7.2.4. Dispense 10 μ L of the antibody mix.

7.2.5. Cover the plate with a sealer and incubate at 4 °C overnight.

7.2.6. Read plate on a microplate reader (50-200 nm flash).

7.3. Human IL-6, IL-8, IL-1 β and TNF- α measurements by electrochemiluminescence

Note: All samples were diluted at 1/150 in diluent 2 (first dilution: 10 μ L in 150 μ L, then 20 μ L in 180 μ L). The protocol followed the supplier's recommendations:

7.3.1. Dilute samples and standard in diluent 2.

7.3.2. Proceed to dilution of the standard in diluent 2 using a 1/4 serial fold dilution.

7.3.3. Wash plates three times with wash buffer.

7.3.4. Dispense 50 μ L of samples or standard per well.

7.3.5. Incubate for 2 h at room temperature under agitation.

7.3.6. Wash the plate four times with PBS + 0.05% Polysorbate 20.

7.3.7. Add 25 μ L of detection antibody (60 μ L of each antibody for 3 mL final) in diluent 3.

7.3.8. Incubate for 2 h at room temperature under agitation.

7.3.9. Wash the plate four times with PBS + 0.05% Polysorbate 20.

7.3.10. Avoiding bubbles, add 150 μ L per well of read buffer (Tris-based buffer containing tripropylamine, diluted 2x in ddH₂O) as a co-reactant for light generation in electrochemiluminescence immunoassays.

7.3.11. Read the plate (without delay) on a multiplex plate reader.

7.4. Mouse TNF- α measurement by ELISA following the supplier's protocol

- 7.4.1. Dilute supernatant 1:1 in assay diluent (ready to use protein-containing buffer).
- 7.4.1.1. Prepare reagents, samples, and standard dilutions as described in the kit. Add 50 μ L of assay diluent to each well.
- 7.4.1.2. Add 50 μ L of standard, control, or sample per well.
- 7.4.2. Mix by gently tapping the plate frame for 1 min.
- 7.4.3. Cover with the provided adhesive strip and incubate for 2 h at room temperature.
- 7.4.4. Aspirate each well and wash with 400 μ L/well (repeat this step five times in total).
- 7.4.5. After the final wash, remove any remaining wash buffer by aspirating.
- 7.4.6. Invert the plate and blot against clean paper towels.
- 7.4.7. Add 100 μ L of mouse TNF- α conjugate to each well. Cover with a new adhesive strip.
- 7.4.8. Incubate for 2 h at room temperature.
- 7.4.9. Repeat the aspiration/wash as in step 7.4.4.
- 7.4.10. Add 100 μ L of substrate solution to each well and incubate for 30 min at room temperature protected from light.
- 7.4.11. Add 100 μ L of diluted hydrochloric acid solution (stop solution) to each well. Gently tap the plate to ensure thorough mixing.
- 7.4.12. Measure the optical density at 450 nm (with the correction wavelength set at 560 nm) using a microplate reader (to be done within 30 min).
- 7.5. Cell viability
- 7.5.1. After removing supernatants from PBMC or monocyte preparations, assess cell viability using a ready to use resazurin solution (oxidation-reduction indicator) added directly to the cell suspension to 10% final concentration.
- 7.5.2. Incubate for 1 to 2 h at 37 $^{\circ}$ C, 5% CO₂.
- 7.5.3. Read fluorescence at 590 nm (Excitation 540 nm) using a microplate reader.

8. Compound Preparation

8.1. Serial dilution for iMoDCs

8.1.1. Dilute the MLT-827 stock solution (10 mM in dimethyl sulfoxide (DMSO) into medium to reach 8 μ M in one go (4x concentrated).

8.1.2. Perform a six-step 1:5 serial dilution, using medium + 0.08% DMSO. Use the same medium + 0.08% DMSO solution for the vehicle (no compound) condition.

8.2. Single dose testing for iMoDCs

8.2.1. Dilute the MLT-827, AFN700 and Cpd11 stock solutions into medium to reach 4 μ M in one go (4x concentrated).

8.3. Serial dilution for murine spleen cells

8.3.1. Dilute a 10 μ M MLT-827 solution (obtained from a 10 mM stock solution following a one go dilution in medium) to 0.01 μ M, with a DMSO end concentration of 0.1%.

8.3.2. For the dilution steps, take 2 μ L of each dilution, add 38 μ L RPMI, and pipet 5 μ L into the well.

Note: All treatments are performed in triplicate.

9. Stimuli Preparation

9.1. Depleted zymosan (DZ)

9.1.1. Add 2 mL of sterile endotoxin-free water to 10 mg of DZ.

9.1.2. Vortex to homogenize the stock solution, vortex also prior each use.

9.1.3. Aliquot solution and store aliquots at -20 °C.

9.2. Trehalose-6,6-dibehenate (TDB)

9.2.1. Add 100 μ L of DMSO to 1 mg TDB, heat at 60 °C in a water bath for 15-30 s.

9.2.2. Vortex and immediately add 900 μ L of sterile PBS, vortex again.

9.2.3. Heat for 10-15 min at 60 °C and homogenize by vortexing prior each use.

9.2.4. Keep the solution at 4 °C.

9.2.5. Perform serial dilutions and single dose preparation as for the MLT-827 compound.

Note: Because TDB needs to be prepared in DMSO, a final 1% DMSO concentration is present during cell stimulation.

REPRESENTATIVE RESULTS:

In myeloid cells, MALT1 relays activation signals downstream of several C-type lectin-like receptors, such as Dectin-1, Dectin-2 and MINCLE⁶. These pathways rely on (hem)ITAM motif-containing receptors (*e.g.*, Dectin-1) or ITAM motif-containing co-receptors (*e.g.*, FcR γ , for Dectin-2 and MINCLE) that recruit and activate the SYK kinase (**Figure 1**). This leads to activation of a protein kinase C isoform, namely PKC δ , which phosphorylates CARD9, thereby triggering CARD9/BCL10/MALT1 complex formation and recruitment of TRAF6 for downstream NF- κ B activation¹². By contrast, the TLR-4 pathway recruits TRAF6 in a MALT1-independent but MYD88/IRAK-dependent manner for NF- κ B activation (**Figure 1**). Evidence for this differential involvement of MALT1 was obtained using genetic models of MALT1 deficiency as well as pharmacological treatment with the peptidic active-site inhibitor z-VRPR-fmk^{11,13,14}.

We used the recently reported potent and selective MALT1 inhibitor MLT-827¹⁵ and asked if this compound would regulate TNF- α production downstream of C type lectin-like and Toll-like receptors, respectively. Human PBMCs and mouse spleen cells were stimulated with depleted zymosan (DZ, a known agonist of Dectin-1) or lipopolysaccharide (LPS, a known agonist of TLR-4) and we measured TNF- α release in the culture supernatant after 20 h. In both the human and the mouse assays, MLT-827 selectively blocked TNF- α production driven by the Dectin-1 pathway, but not by the TLR-4 pathway (**Figure 2**). We obtained similar data upon incubation with the z-VRPR-fmk compound (Supplementary **Figure 1**).

To gain pathway insights, we conducted further experiments in human monocytes and in immature monocytes-derived dendritic cells (iMoDCs), comparing the effect of MLT-827 to that of the SYK inhibitor Cpd11¹⁶ and to that of the IKK β inhibitor AFN700¹⁵. In monocytes stimulated with LPS, production of TNF- α was almost completely abrogated by AFN700 but was not sensitive to Cpd11 (**Figure 3A**), which is consistent with the dependency/independency of the TLR-4 pathway on NF- κ B/SYK activity, respectively (see **Figure 1**). By contrast, TNF- α production driven by Dectin-1 in iMoDCs displayed sensitivity to Cpd11 in addition to sensitivity to MLT-827 and AFN700 (**Figure 3B**, Supplementary **Figure 2**), providing further evidence for involvement of a SYK/CBM signaling cascade in the Dectin-1 pathway (**Figure 1**). Noteworthy, production of IL-1 β , IL-6 and IL-23 upon Dectin-1 stimulation was also sensitive to the three inhibitors, thereby indicating regulatory mechanisms similar to TNF- α . However, a limited effect of the three compounds on IL-8 production suggested a distinct regulatory mechanism for this cytokine (**Figure 3B**, Supplementary **Figure 2**).

In addition to Dectin-1, other CLLRs, such as Dectin-2 and MINCLE, function via stimulation of a CARD9 signalosome⁷. We therefore tested MLT-827 in iMoDCs challenged with the MINCLE agonist Trehalose-6,6-dibehenate (TBD). Raising TBD concentrations above 50 μ g/mL led to production of TNF- α , IL-6 and IL-1 β , which relied on MALT1 paracaspase activity as seen from the

blocking effect of MLT-827 (**Figure 4A**). Consistent results were obtained when challenging iMoDCs with increasing concentrations of DZ to stimulate Dectin-1 (**Figure 4B**).

FIGURE LEGENDS:

Figure 1: NF- κ B signaling downstream of Dectin-1, MINCLE and TLR-4. The cartoon depicts the key features of canonical NF- κ B activation pathways downstream of Dectin-1, Dectin-2, MINCLE or TLR-4 in myeloid cells. The hemITAM-containing Dectin-1 receptor¹⁷ can directly engage SYK to stimulate CBM (CARD9/BCL10/MALT1) complex formation, leading to TRAF6 dependent NF- κ B activation. Other C-type Lectin-like receptors such as Dectin-2 or MINCLE need to recruit an ITAM-containing FcR γ chain to engage a CBM and activate NF- κ B. TLR-4 receptors use another mechanism for NF- κ B activation, relying on MYD88 and IRAK1/IRAK4 kinases upstream of TRAF6.

Figure 2: Dectin-1 signals via MALT1 for production of TNF- α in human and mouse cells. (A) Human PBMCs data as in Unterreiner *et al.*, 2017 (Figure 2A of Ref. 11). Human PBMCs were stimulated with 1 ng/mL of LPS (TLR-4 agonist) or 100 μ g/mL DZ (Dectin-1 agonist) for 20 h in the presence of graded concentrations of MLT-827. TNF- α released in the supernatant was quantified by HTRF. (B) Mouse spleen cells were treated with a concentration range of MLT-827 for 30 min and subsequently stimulated with 30 μ g/mL DZ or 1 μ g/mL LPS + 10 ng/mL IFN- γ for 18 h. TNF- α in the cell culture supernatant was measured by ELISA. One of two experiments with similar results is shown, as means \pm SEM of three measurements.

Figure 3: IKK β - and/or SYK-dependency of cytokine production downstream of TLR-4 and Dectin-1. (A) Human monocytes were pre-treated for 1 h with MLT-827 (1 μ M), Cpd11 (1 μ M), or AFN700 (3 μ M) or vehicle (DMSO). Cells were stimulated with 10 ng/mL LPS for 20 h and TNF- α in the supernatant was quantified by HTRF. (B) TNF- α , IL-1 β , IL-6, IL-23 and IL-8 production by human monocytes-derived dendritic cells (iMoDCs) stimulated for 24 h with DZ (100 μ g/mL) after 1 h pre-incubation with MLT-827, Cpd11, AFN700 (all at 1 μ M) or DMSO. Cytokine levels in DMSO-treated samples were set at 100%. Data are means \pm SD of three measurements, and are representative of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired two-tailed Student's t test.

Figure 4: C type lectin-like-dependent cytokine production by iMoDCs. TNF- α , IL-1 β , and IL-6 production by iMoDCs stimulated for 24 h with the MINCLE agonist Trehalose-6,6-dibehenate (TDB, 100 μ g/mL) (A) or with the Dectin-1 agonist DZ (100 μ g/mL) (B) after 1 h pre-incubation with MLT-827 (1 μ M) or DMSO. Data are means \pm SD of three measurements and are representative of three independent experiments.

DISCUSSION:

In this work, we used simple experimental settings to study signaling pathways in human and mouse innate cells, and interrogate their dependency on MALT1 proteolytic function. Expanding on previous work¹¹, our study showed that MALT1 paracaspase activity controls C-type lectin-like receptor induced cytokine production, including TNF- α . In contrast, TLR-4-induced TNF- α was independent of MALT1 in both species. Collectively, these data corroborated the key and

selective contribution of the MALT1/CBM signalosome downstream of C-type lectin-like receptors, which was unveiled by earlier studies^{6,12,18}.

Whether the clear independency of TLR-4 signaling on MALT1 in myeloid cells applies to other cell types remains to be explored. For instance, in B-lymphocytes, TLR signaling was previously shown to contribute to B-cell activation downstream of the B-cell antigen receptor¹⁹. In fact, we have unpublished evidence that TLR-4 stimulated human and mouse B cells display sensitivity to MLT-827. Therefore, further mechanistic insights downstream of the B-cell receptor will be valuable. In this context, a recent study in B cell lymphoma provided evidence for clustering of the signaling pathways downstream of the B-cell receptor and the TLR9 receptor²⁰. TRAF6, which acts as a mediator for NF- κ B activation in both the B-cell receptor and the TLR pathways, might be a point of crosstalk, which could explain the sensitivity of both pathways to MALT1 protease inhibition. Conversely, TRAF6 is also a common downstream player of CLLRs and TLRs for induction of NF- κ B but these two pathways do not appear to crosstalk in a MALT1 paracaspase-dependent manner in myeloid cells.

This work focused on cytokine production, which provides an easy readout for signaling pathways and can be implemented readily for compound profiling. It highlighted the value of selective and potent inhibitors of MALT1 for unravelling MALT1 biology. Obtaining further mechanistic insights will require additional work and development of more proximal assays, *e.g.*, to characterize the substrates of MALT1 involved in innate signaling regulation.

ACKNOWLEDGMENTS:

We thank Elsevier for their authorization (license number 4334770630127) to reproduce here **Figure 2A** from Unterreiner *et al.* (2017).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES

1. Coornaert, B. *et al.* T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. *Nature immunology*. **9** (3), 263–71 (2008).
2. Rebeaud, F. *et al.* The proteolytic activity of the paracaspase MALT1 is key in T cell activation. *Nature immunology*. **9** (3), 272–281 (2008).
3. Jaworski, M., Thome, M. The paracaspase MALT1: Biological function and potential for therapeutic inhibition. *Cellular and Molecular Life Sciences*. **73** (3), 459–473 (2016).
4. Meininger, I., Krappmann, D. Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome. *Biological Chemistry*. **397** (12), 1315–1333 (2016).
5. Qiao, Q. *et al.* Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. *Molecular cell*. **51** (6), 766–79 (2013).
6. Gross, O. *et al.* Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. *Nature*. **442** (7103), 651–656 (2006).
7. Chiffolleau, E. C-type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. *Frontiers in Immunology*. **9** (FEB), 1–9

570 (2018).

571 8. Taylor, P.R. *et al.* Dectin-1 is required for beta-glucan recognition and control of fungal
572 infection. *Nature Immunology*. **8** (1), 31–38 (2007).

573 9. Lanternier, F. *et al.* Primary immunodeficiencies underlying fungal infections. *Current*
574 *opinion in pediatrics*. **25** (6), 736–47 (2013).

575 10. Thome, M. Multifunctional roles for MALT1 in T-cell activation. *Nature reviews*.
576 *Immunology*. **8** (7), 495–500 (2008).

577 11. Unterreiner, A., Stoehr, N., Huppertz, C., Calzascia, T., Farady, C.J., Bornancin, F. Selective
578 MALT1 paracaspase inhibition does not block TNF- α production downstream of TLR-4 in myeloid
579 cells. *Immunology Letters*. **192** (October), 48–51 (2017).

580 12. Strasser, D. *et al.* Syk Kinase-Coupled C-type Lectin Receptors Engage Protein Kinase C- δ
581 to Elicit Card9 Adaptor-Mediated Innate Immunity. *Immunity*. **36** (1), 32–42 (2012).

582 13. Jaworski, M. *et al.* Malt1 protease inactivation efficiently dampens immune responses but
583 causes spontaneous autoimmunity. *The EMBO journal*. **33** (23), 2765–81 (2014).

584 14. Yu, J.W. *et al.* MALT1 protease activity is required for innate and adaptive immune
585 responses. *PLoS ONE*. **10** (5), 1–20 (2015).

586 15. Bardet, M. *et al.* The T-cell fingerprint of MALT1 paracaspase revealed by selective
587 inhibition: *Immunology and Cell Biology*. **96** (1) 81-99 (2018).

588 16. Thoma, G. *et al.* Discovery and profiling of a selective and efficacious syk inhibitor. *Journal*
589 *of Medicinal Chemistry*. **58** (4), 1950–1963 (2015).

590 17. Bauer, B., Steinle, A. HemITAM: A single tyrosine motif that packs a punch. *Science*
591 *Signaling*. **10** (508), 1–10 (2017).

592 18. Gringhuis, S.I. *et al.* Selective c-Rel activation via Malt1 controls anti-fungal TH-17
593 immunity by dectin-1 and dectin-2. *PLoS Pathogens*. **7** (1) (2011).

594 19. Dufner, A., Schamel, W.W. B cell antigen receptor-induced activation of an IRAK4-
595 dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model. *Cell*
596 *Communication and Signaling*. **9** (1), 6 (2011).

597 20. Phelan, J.D. *et al.* A multiprotein supercomplex controlling oncogenic signalling in
598 lymphoma. *Nature*. In press (2018).

599

Figure 1




Figure 2




Figure 3





A**B**

Figure 4

A**B**

Name of Material/Equipment	Company	Catalog number
100 µm nylon cell strainer	Sigma	CLS431752
14 ml Falcon tube	BD Falcon	352057
15 mL Falcon tube	Falcon	352090
50 mL Falcon tube	Falcon	352070
6 well plates	Costar	3516
96 well flat-bottom plate, with low evaporation lid	Costar	3595
96 well V-bottom plate	Costar	734-1798
Ammonium Chloride - NH ₄ Cl	Sigma	A9434
Assay diluent RD1-W ELISA	R&D	895038
Cell culture microplate, 384 well, black	Greiner	781986
Depleted Zymosan	Invivogen	tlrl-dzn
Dimethyl sulfoxide	Sigma	D2650
EDTA-Na ₂	Sigma	E5134
ELISA muTNF-α	R&D	SMTA00
Ficoll-Paque Plus	GE Healthcare	17-1440-03
gentleMACS C tubes	MACS Miltenyi Biotec	130-096-334
gentleMACS dissociator	MACS Miltenyi Biotec	130-093-235
GM-CSF	Novartis	-
Heat-inactivated Fetal bovine serum	Gibco	10082
HTRF hu IL-23	CisBio	62HIL23PEG
HTRF hu TNF-α	CisBio	62TNFPEC
HTRF reconstitution buffer	CisBio	62RB3RDE
IFN-γ	R&D	L4516
IL-4	Novartis	-
Isoflurane	Abbott	Forene
Lipopolysaccharides (LPS)	Sigma	L4391
Lipopolysaccharides	Sigma	L4516
Lysis buffer	Self-made	-
Magnet	Stemcell	18001
Microplate, 384 well white	Greiner	784075
Monocytes enrichment kit	Stemcell	19059
Nalgene Mr. Frosty Cryo 1 °C Freezing Container	Nalgene	5100-0001
PBS 1x pH 7.4 [-] CaCl ₂ [-] MgCl ₂	Gibco	10010
Penicillin/Streptomycin	Gibco	15140
Potassium bicarbonate - KHCO ₃	Sigma	P9144
PrestoBlue	Invitrogen	A13262
Propanol-2	Merck	1.09634
Read buffer	MesoScale Discovery	R92TC-3
Recovery cell culture freezing medium	Gibco	12648-010
Roswell Park Memorial Institute Medium (RPMI) with Glutamax	Gibco	61870
Separation buffer	Self-made	-
Sodium Pyruvate	Gibco	11360
Trehalose-6,6-dibehenate	Invivogen	tlrl-tdb
Tween 20	Sigma	P7949
UltraPure 0.5 M EDTA pH 8.0	Invitrogen	15675
Viewseal sealer	Greiner BioOne	676070
V-PLEX Proinflammatory Panel 1 Human Kit	MesoScale Discovery	K15049D
β-Mercaptoethanol	Gibco	31350

Comments/Description
Assay diluent
now: tlr-zyd
DMSO
Ethylenediaminetetraacetic acid disodium salt dihydrate
FBS
50mM Phosphate buffer, pH 7.0, 0.8M KF, 0.2% BSA
LPS used in human samples
LPS used in murine samples
155 mM NH ₄ Cl, 10 mM KHCO ₃ , 1 mM EDTA, pH 7.4
cooling device (containing Propanol-2)
Phosphate-buffered saline
Pen/Strep
Resazurin solution for viability assessment
Tris-based buffer containing tripropylamine
freezing medium
+ 10% FBS for iMoDCs
+ 10% FBS + 1 mM Sodium Pyruvate + 100 U/mL Pen/Strep + 5 µM β-mercaptoethanol for human PBMCs and monocytes
+ 10% FBS + Pen/Strep + 5 µM β-mercaptoethanol for murine splenocytes
PBS pH 7.4 + 2% FBS + 1 mM EDTA pH 8.0
TDB
Polysorbate 20
Ethylenediaminetetraacetic acid
electrochemiluminescent multiplex assay (IL-1β, TNF-α, IL-6, IL-8)



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Author(s):

*Myeloid Innate Signaling Pathway Regulation by
MALTI peracetylation activity
Unterreiner, Tami, Anastasi, Dubois, Miwa, Calzavara,
Bornancin*

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:

BORNANCIN FREDERIC

Department:

Autoimmunity Transplantation Inflammation

Institution:

NOVARTIS

Title:

PhD

Signature:

Frederic Bornancin

Date:

24 Jul 2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

The present study examined the impact of gene inhibitor in human and mouse myeloid cells. The paper is not well written, and the results are not presented in a clear manner, there are a number of significant issues that need to be addressed.

Major Concerns:

1. In Abstract, the authors should list the important findings of this work.
> *We thank the reviewer for spotting this deficiency. We have now addressed this comment, in both the short- and the long- abstract.*
2. It would be useful to determine the effect of key genes on TNF- α production by RNAi.
> *Here, TNF- α production was used as a readout to compare the impact of MALT1 on CLLR and TLR signaling pathways. Therefore, we have focused our work on the effects of MLT-827, a well-characterized inhibitor. The aim of this short manuscript was to describe protocols for testing MLT-827. It was not to investigate the biology of the signaling pathways beyond involvement of MALT1 and the CBM complex.*
3. In REPRESENTATIVE RESULTS, there are many places that are difficult to follow. The reviewer cannot understand the difference between Figure 2 and 3. This should explained in detail.
> *We have now added information in the legends for these two figures to guide the reader.*
4. In Figure 2, the authors should employ other marker(s) in addition to TNF- α .
> *TNF- α was used as a first line, robust cytokine readout. We also monitored other cytokines and the results are presented in Fig. 3B.*

Reviewer #2:

This study shows that in both human and mouse cells MALT1 paracaspase activity controls C-type lectin-like receptor, but not TLR4, induced cytokine production, including TNF- α . Collectively, these data provide solid evidence corroborating the key and selective contribution of the CBM signalosome downstream of C-type lectin-like receptors, which was unveiled by earlier studies. The data is worth of publication.

Reviewer #3:

Manuscript Summary:

The authors use a selective inhibitor of MALT1 in human and mouse myeloid cells to demonstrate the important role of this protein in the signaling cascade downstream CLRs. The protocol is well detailed and will serve a useful resource in the field. This reviewer recommends publication with minor revisions below.

Major Concerns:

None

Minor Concerns:


Dectin-1 signals via a single copy tyrosine signaling module termed the hemi-immunoreceptor tyrosine-based activation motif (hemITAM) - please see Marakalala & Ndlovu, Plos Pathogens 2017 or Bauer & Steinle, Sci Signal, 2017. This is not exactly the same as ITAM, and it should be accurately depicted in the cartoon and legend in Figure 1.

> *We thank the reviewer for this valuable insight. We corrected Fig. 1 accordingly.*

It will be helpful if the authors indicated the statistical significance (as it was done in figure 2B) of the results/ individual points in Figure 4A and B.

> *We have added any missing information in the figure legends.*


Supplementary Figure 1



Supplementary Figure 1: Z-VRPR-fmk inhibits DZ-induced but not LPS/IFN γ -induced TNF- α production in mouse splenocytes.

TNF- α cytokine secretion in murine spleen cells treated with Z-VRPR-fmk and stimulated with either 30 $\mu\text{g/mL}$ of DZ (left panel) or with 1 μM LPS B8 + 10 ng/mL of IFN- γ (right panel) for 20 h. Data are means \pm SD and representative of at least three independent experiments. The condition without compound was set as control. Spon represent the condition without stimulation and compound.

Supplementary Figure 2



Supplementary Figure 2: MALT1- dependent cytokine release in Dectin-1 stimulated dendritic cells.

Dose dependent inhibition of IL-8, IL-1 β , TNF- α , IL-6 and IL-23 cytokine secretion in iMoDCs treated with MLT-827 and stimulated with Depleted Zymosan (100 μ g/mL) for 24 h. Data are means \pm SEM and representative of at least three independent experiments. The lowest concentration of compound tested was set as control.